Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Jun;45(6):821–829. doi: 10.1038/bjc.1982.133

Clonal variation in the sensitivity of B16 melanoma to m-AMSA.

T C Stephens, J H Peacock
PMCID: PMC2011041  PMID: 6896455

Abstract

A hypothesis that m-AMSA may have greater cytotoxicity in melanin-containing tumour tissues, because it may reversibly bind to melanin, leading to prolonged drug exposure, was examined. Clonal lines of B16 melanoma which differed widely in pigmentation level were selected by isolating artificial lung colonies and in vitro soft-agar colonies, and implanting them into mice. Excision cell-survival assays performed 24 h after drug administration showed that in vivo sensitivity to m-AMSA progressively increased as pigmentation level decreased, but that m-AMSA drug levels measured 24 h after treatment were much lower in amelanotic than in melanotic lines. In dose-survival studies the reduced sensitivity of melanotic cell lines was revealed as a large shoulder (Dq = 27 mg/kg) though the terminal slopes for melanotic and amelanotic cell lines were similar (D10 approximately 31 mg/kg). Time-course studies indicated that there was no significant loss of drug from a melanotic cell line for 72 h after drug administration, though in an amelanotic cell line drug levels fell 10-fold in 10 h. There was, however, no evidence for prolonged drug cytotoxicity in the melanotic cell line. Using a fractionated drug-treatment regime, the greater cytotoxicity of m-AMSA to amelanotic tumour tissue was confirmed in a non-invasive regrowth-delay assay.

Full text

PDF
821

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cain B. F., Atwell G. J. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer. 1974 Aug;10(8):539–549. doi: 10.1016/0014-2964(74)90079-6. [DOI] [PubMed] [Google Scholar]
  2. Cain B. F., Seelye R. N., Atwell G. J. Potential antitumor agents. 14. Acridylmethanesulfonanilides. J Med Chem. 1974 Sep;17(9):922–930. doi: 10.1021/jm00255a003. [DOI] [PubMed] [Google Scholar]
  3. Courtenay V. D. A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse. Br J Cancer. 1976 Jul;34(1):39–45. doi: 10.1038/bjc.1976.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gormley P. E., Cysyk R. L. A fluorescence assay for 4'-(9-acridinylamino)methanesulfon-m-anisidide, a new antitumor agent. Anal Biochem. 1979 Jul 15;96(2):504–507. doi: 10.1016/0003-2697(79)90613-4. [DOI] [PubMed] [Google Scholar]
  5. Gormley P. E., Sethi V. S., Cysyk R. L. Interaction of 4'-(9-acridinylamino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases. Cancer Res. 1978 May;38(5):1300–1306. [PubMed] [Google Scholar]
  6. Hill R. P., Stanley J. A. The lung-colony assay: extension to the Lewis lung tumour and the B16 melanoma--radiosensitivity of B16 melanoma cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1975 Apr;27(4):377–387. doi: 10.1080/09553007514550351. [DOI] [PubMed] [Google Scholar]
  7. Issell B. F. Amsacrine (AMSA). Cancer Treat Rev. 1980 Jun;7(2):73–83. doi: 10.1016/s0305-7372(80)80017-x. [DOI] [PubMed] [Google Scholar]
  8. Rozencweig M., Von Hoff D. D., Cysyk R. L., Muggia F. M. m-AMSA and PALA: two new agents in cancer chemotherapy. Cancer Chemother Pharmacol. 1979;3(3):135–141. doi: 10.1007/BF00262414. [DOI] [PubMed] [Google Scholar]
  9. Shoemaker D. D., Legha S. S., Cysyk R. L. Selective localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in B 16 melanoma. Pharmacology. 1978;16(4):221–225. doi: 10.1159/000136771. [DOI] [PubMed] [Google Scholar]
  10. Steel G. G., Adams K. Stem-cell survival and tumor control in the Lewis lung carcinoma. Cancer Res. 1975 Jun;35(6):1530–1535. [PubMed] [Google Scholar]
  11. Stephens T. C., Currie G. A., Peacock J. H. Repopulation of gamma-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors. Br J Cancer. 1978 Nov;38(5):573–582. doi: 10.1038/bjc.1978.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Stephens T. C., Peacock J. H. Cell yield and cell survival following chemotherapy of the B16 melanoma. Br J Cancer. 1978 Nov;38(5):591–598. doi: 10.1038/bjc.1978.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Stephens T. C., Peacock J. H., Sheldon P. W. Influence of in vitro assay conditions on the assessment of radiobiological parameters of the MT tumour. Br J Radiol. 1980 Dec;53(636):1182–1187. doi: 10.1259/0007-1285-53-636-1182. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES